Edwards Lifesciences (NYSE:EW – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.670-0.710 for the period, compared to the consensus estimate of 0.690. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. Edwards Lifesciences also updated its Q3 guidance to $0.67-0.71 EPS.
Edwards Lifesciences Stock Down 31.3 %
EW traded down $27.25 during midday trading on Thursday, hitting $59.70. The company had a trading volume of 45,810,475 shares, compared to its average volume of 3,698,478. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $35.98 billion, a price-to-earnings ratio of 26.20, a PEG ratio of 3.19 and a beta of 1.11. The stock’s 50 day moving average price is $89.12 and its 200 day moving average price is $87.12.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the firm posted $0.66 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. On average, research analysts anticipate that Edwards Lifesciences will post 2.77 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on Edwards Lifesciences
Insider Buying and Selling
In other news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the transaction, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 81,099 shares of company stock worth $7,003,553. 1.29% of the stock is owned by company insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
- Five stocks we like better than Edwards Lifesciences
- Bank Stocks – Best Bank Stocks to Invest In
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What is a Death Cross in Stocks?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.